CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 117 enrolled
Drug / intervention
Fluarix/Influsplit Tetra® (2013-2014 season)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01878812
NCT01878812Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra® (2013/2014 Season) in Adults 18 Years of Age and Older

GlaxoSmithKline·interventional·Posted Jun 17, 2013·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating Fluarix/Influsplit Tetra® (2013-2014 season) for Influenza. Completed, enrolled 117 participants across 4 sites.

Detailed Summary

The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit Tetra containing the four influenza strains (two A strains and two B strains) for the 2013/2014 season.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 17, 2013
Enrollment StartJul 11, 2013
Primary CompletionAug 5, 2013
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 13.0 years ago

Interventions

Fluarix/Influsplit Tetra® (2013-2014 season)biological

1 dose administered intramuscularly in the deltoid region of non-dominant arm